1063733-41-4

Usage

Uses

Used in Pharmaceutical Research and Development:
N-[(2,4-dimethoxyphenyl)methyl]-1,2,4-thiadiazol-5-amine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds due to its potential pharmacological and biological activities.
Used in Antimicrobial Applications:
In the field of antimicrobial research, N-[(2,4-dimethoxyphenyl)methyl]-1,2,4-thiadiazol-5-amine is used as an active ingredient for developing new antimicrobial agents, leveraging its potential to combat resistant strains of bacteria and other pathogens.
Used in Antioxidant Formulations:
N-[(2,4-dimethoxyphenyl)methyl]-1,2,4-thiadiazol-5-amine is used as an antioxidant in formulations to protect against oxidative stress and related cellular damage, which is crucial in the development of treatments for various diseases and conditions associated with oxidative stress.
Used in Anticancer Research:
N-[(2,4-dimethoxyphenyl)methyl]-1,2,4-thiadiazol-5-amine is used as a potential anticancer agent in cancer research, where it may be evaluated for its ability to inhibit the growth and proliferation of cancer cells.
Used in Anti-inflammatory and Analgesic Applications:
In the development of anti-inflammatory and analgesic drugs, N-[(2,4-dimethoxyphenyl)methyl]-1,2,4-thiadiazol-5-amine is used for its potential to reduce inflammation and alleviate pain, which could be beneficial in treating a range of inflammatory and painful conditions.
Used in Drug Delivery Systems:
N-[(2,4-dimethoxyphenyl)methyl]-1,2,4-thiadiazol-5-amine may be utilized in the design of drug delivery systems to improve the bioavailability and therapeutic efficacy of various pharmaceutical agents, particularly in the context of targeted drug delivery to specific tissues or cells.

Upstream product

• 7552-07-0 1,3,4-thiadiazol-5-amine 
• 613-45-6 2,4-Dimethoxybenzaldehyde 
• 56553-60-7 sodium tris(acetoxy)borohydride 

Downstream Products

• 1354786-67-6 3-Cyano-N-(2,4-dimethoxybenzyl)-4-{[3-pyridazin-4-yl-3'-(trifluoromethyl)biphenyl-4-yl]oxy}-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1354786-68-7 3-Cyano-N-(2,4-dimethoxybenzyl)-4-{[3-pyridazin-4-yl-2'-(trifluoromethyl)biphenyl-4-yl]oxy}-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1235406-41-3 3-cyano-N-[(2,4-dimethoxyphenyl)methyl]-4-fluoro-N-(1,2,4-thiadiazol-5-yl)benzene-1-sulfonamide 
• 1354917-73-9 3-cyano-N-(2,4-dimethoxybenzyl)-4-[(3-methoxyphenyl)thio]-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1354917-93-3 3-cyano-N-(2,4-dimethoxybenzyl)-4-[2-methoxy-4-(trifluoromethyl)benzyl]-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1354917-98-8 3-cyano-N-(2,4-dimethoxybenzyl)-4-[2-pyridazin-4-yl-4-(trifluoromethyl)benzyl]-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1354917-64-8 3-cyano-N-(2,4-dimethoxybenzyl)-4-[(2-methoxyphenyl)thio]-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1354917-72-8 3-cyano-N-(2,4-dimethoxybenzyl)-4-[(4-methoxyphenyl)thio]-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1354917-79-5 3-cyano-N-(2,4-dimethoxybenzyl)-4-{[2-pyridazin-4-yl-4-(trifluoromethyl)phenyl]thio}-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1354917-89-7 3-cyano-N-(2,4-dimethoxybenzyl)-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1354917-87-5 4-bromo-3-cyano-N-(2,4-dimethoxybenzyl)-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1423161-80-1 tert-butyl 8-(6-(N-(2,4-dimethoxybenzyl)-N-(1,2,4-thiadiazol-5-yl)sulfamoyl)-1-methyl-1H-indol-3-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1423162-03-1 N-(2,4-dimethoxybenzyl)-4-fluoro-3-nitro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide 
• 1423161-85-6 3-bromo-N-(2,4-dimethoxybenzyl)-1-methyl-N-(1,2,4-thiadiazol-5-yl)-1H-indole-6-sulfonamide 

Relevant academic research and scientific papers

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7

A series of acidic diaryl ether heterocyclic sulfonamides that are potent and subtype selective NaV1.7 inhibitors is described. Optimization of early lead matter focused on removal of structural alerts, improving metabolic stability and reducing cytochrome P450 inhibition driven drug-drug interaction concerns to deliver the desired balance of preclinical in vitro properties. Concerns over nonmetabolic routes of clearance, variable clearance in preclinical species, and subsequent low confidence human pharmacokinetic predictions led to the decision to conduct a human microdose study to determine clinical pharmacokinetics. The design strategies and results from preclinical PK and clinical human microdose PK data are described leading to the discovery of the first subtype selective NaV1.7 inhibitor clinical candidate PF-05089771 (34) which binds to a site in the voltage sensing domain.

Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors

The majority of potent and selective hNaV1.7 inhibitors possess common pharmacophoric features that include a heteroaryl sulfonamide headgroup and a lipophilic aromatic tail group. Recently, reports of similar aromatic tail groups in combination with an acyl sulfonamide headgroup have emerged, with the acyl sulfonamide bestowing levels of selectivity over hNaV1.5 comparable to the heteroaryl sulfonamide. Beginning with commercially available carboxylic acids that met selected pharmacophoric requirements in the lipophilic tail, a parallel synthetic approach was applied to rapidly generate the derived acyl sulfonamides. A biaryl acyl sulfonamide hit from this library was elaborated, optimizing for potency and selectivity with attention to physicochemical properties. The resulting novel leads are potent, ligand and lipophilic efficient, and selective over hNaV1.5. Representative lead 36 demonstrates selectivity over other human NaV isoforms and good pharmacokinetics in rodents. The biaryl acyl sulfonamides reported herein may also offer ADME advantages over known heteroaryl sulfonamide inhibitors.

Sulfonamide compound as sodium channel blocker and application thereof

The invention provides a sulfonamide compound as a sodium channel blocker and an application of the sulfonamide compound, and the sulfonamide compound has dual inhibitory activity on Nav1.7 and Nav1.3 at the same time and can be used as a medicine for tre

4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS

Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.

Sulfonamide compound used as sodium channel blocker, and application thereof

The invention provides a sulfonamide compound used as a sodium channel blocker, and an application thereof. The sulfonamide compound has dual inhibitory activity on Nav1.7 and Nav1.3 at the same time,and can be used as a medicine for widely treating pains

Sulfonamide compound used as sodium channel blocker, and application thereof

The invention provides a sulfonamide compound used as a sodium channel blocker, and an application thereof. The sulfonamide compound has dual inhibitory activity on Nav1.7 and Nav1.3 at the same time,and can be used as a medicine for widely treating pains.

DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS

Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and R1A to R4A are defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic

Highly potent and selective NaV1.7 inhibitors for use as intravenous agents and chemical probes

The discovery and selection of a highly potent and selective NaV1.7 inhibitor PF-06456384, designed specifically for intravenous infusion, is disclosed. Extensive in vitro pharmacology and ADME profiling followed by in vivo preclinical PK and efficacy model data are discussed. A proposed protein–ligand binding mode for this compound is also provided to rationalise the high levels of potency and selectivity over inhibition of related sodium channels. To further support the proposed binding mode, potent conjugates are described which illustrate the potential for development of chemical probes to enable further target evaluation.

Benzoxazolinone aryl sulfonamides as potent, selective Nav1.7 inhibitors with in vivo efficacy in a preclinical pain model

Studies on human genetics have suggested that inhibitors of the Nav1.7 voltage-gated sodium channel hold considerable promise as therapies for the treatment of chronic pain syndromes. Herein, we report novel, peripherally-restricted benzoxazoli

Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models

We report on a novel series of aryl sulfonamides that act as nanomolar potent, isoform-selective inhibitors of the human sodium channel hNaV1.7. The optimization of these inhibitors is described. We aimed to improve potency against hNaV1.7 while minimizing off-target safety concerns and generated compound 3. This agent displayed significant analgesic effects in rodent models of acute and inflammatory pain and demonstrated that binding to the voltage sensor domain 4 site of NaV1.7 leads to an analgesic effect in vivo. Our findings corroborate the importance of hNaV1.7 as a drug target for the treatment of pain.